xt ... grey is a bagholder and the official cheerleader for SRPT. He saw his shares cut in half in January and now desperate to break even. Just ignore him, he is an idiot. Go back and read his posts from December and early January. Anything you post that is against his trail of thought makes you his enemy. He acts like a grade 2 student.
grey .... you couldn't care less about the kids suffering from this horrible disease, YOUR ONLY CONCERN IS TO PROFIT FROM THIS, TELL THE TRUTH. ROTFL
Dude ... BMRN's panel meeting a few months back DID NOT HAVE TO VOTE whether to approve the drug. You are acting really smart but the bottom line from your posts prior to Jan 22nd meeting, you were nothing but a cheerleader and you learnt your lesson the hard way seeing the share price drop from $40 in late December down to $10 most recently.
grey .... Are the panel of doctor's expected to vote on April 25th whether to Approve the drug? Where can I find the panel questions?
The big difference between ACAD and CLVS is there are NO APPROVED drug for Parkinson disease making it an UNMET MEDICAL NEED. As for CLVS, Astra Zeneca has a much superior drug in the market making CLVS' drug IRRELEVANT.
Sentiment: Strong Sell
Adam Feuerstein does not need to be investigated, however you need to get your head examined to see if you have a brain to be buying this garbage stock.
You are an ill-informed idiot holding an empty bag. CLVS will trade below $10 on April 13th. CLVS management trapped idiots like into buying their shares while they were selling theirs over $100. ROTFL
Sentiment: Strong Sell
Don't know what to think of it but if true, they may get a negative response from Adcom. Briefing document will set the tone.
Positive briefing document released today. This bodes well. My only concern is market cap already at $2.25 Billion, not sure how much of the good news is baked in.
Thank you all for replying to me. I guess we just have to sit tight wait for the news. Based on what I've read and understood, PTLA is significantly undervalued at this level. I see an easy double if not more if the data meets its primary endpoints and FDA approves the other drug in August.
Sentiment: Strong Buy
I am referring to APEX data;
This is from their earnings press release;
Plan to report topline results from the 7,514-patient pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in early April.
Plan to submit a New Drug Application to the FDA in the second half of 2016, subject to positive APEX data.
I have shares that I bought in the high $40s and was wondering if good data will take the share price back up.